피부과 치료제 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 유형별, 투여 경로별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Dermatological Drugs Market Growth & Trends:

The global dermatological drugs market size is expected to reach USD 42.3 billion by 2030, expanding at a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases, nutritional deficiency due to unhealthy food habits, increasing awareness when it comes to lifestyle diseases, and increasing pollution levels, and lack of immunity in the population. Additionally, the rising per capita income and the increasing purchasing power are the driving forces in this market.

The acne segment is expected to expand with a CAGR of 10.5% from 2022 to 2028. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts. Additionally, infected hair follicles cause acne, which starts from the skin's pores. Acne causes bumps on the face, shoulders, chest, and back in the form of pimples, blackheads, and whiteheads. Acne can be cured, and the appearance of the skin can be improved with effective treatment from dermatologists, contributing to the dermatological drug market.

North America held the largest revenue share of more than 35% in 2021. The U.S. is positively contributing to the growth of the regional market. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth. This region is one of the promising regions to launch new technology in terms of healthcare infrastructure and advanced research and development activities that help innovate and produce the most appropriate drugs to cure cancer. It is observed that in the region, there is a rapid shift in the healthcare industry to consumer-driven from traditional treatment for providing diagnosis and provision-based health services. Additionally, ease of availability of drugs and reimbursement policies for the patient in the healthcare industry contributes to driving the market in the region.

Dermatological Drugs Market Report Highlights:

• The psoriasis segment dominated the market with the largest revenue share of 50.6% in 2024, which can be attributed to the awareness of the disease and the demand for effective treatments.
• The prescription segment dominated the market for the largest revenue share of 61.9% in 2024 and is expected to grow over the fastest CAGR of 10.4% over the forecast period.
• Topical administration dominated the market with the largest revenue share of 60.0% in 2024.
• Corticosteroids dominated the market with the largest revenue share of 30.1% in 2024. This can be attributed to rising skin infection cases and the growth of research and development.
• Retail pharmacies dominated the market, with the largest revenue share of 50.6% in 2024. This can be attributed to OTC dermatological product growth and awareness of skin conditions.
• The dermatological drugs market in North America dominated the market with the largest revenue share of 38.6% in 2024, which can be attributed to advancements in drug development and increasing awareness.
• The North America Dermatological Drugs market had the largest revenue share of 33.6% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Dermatological Drugs Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Dermatological Drugs Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining Power of the Suppliers
    • 3.4.1.2. Bargaining Power of the Buyers
    • 3.4.1.3. Threats of Substitution
    • 3.4.1.4. Threats from New Entrants
    • 3.4.1.5. Competitive Rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political Landscape
    • 3.4.2.2. Economic and Social Landscape
    • 3.4.2.3. Technological Landscape
    • 3.4.2.4. Environmental Landscape
    • 3.4.2.5. Legal Landscape

Chapter 4. Dermatological Drugs Market: Therapy Estimates & Trend Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Acne
  • 4.4.1. Acne Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Psoriasis
  • 4.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Rosacea
  • 4.6.1. Rosacea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Alopecia
  • 4.7.1. Alopecia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Dermatological Drugs Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Prescription
  • 5.4.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Over-the-counter (OTC)
  • 5.5.1. Over-the-counter (OTC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Topical Administration
  • 6.4.1. Topical Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Oral Administration
  • 6.5.1. Oral Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Parenteral Administration
  • 6.6.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis

• 7.1. Drug Class Market Share, 2024 & 2030
• 7.2. Drug Class Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 7.4. Corticosteroids
  • 7.4.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Retinoids
  • 7.5.1. Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Antibiotics
  • 7.6.1. Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Antifungals
  • 7.7.1. Antifungals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Calcineurin Inhibitors
  • 7.8.1. Calcineurin Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2030
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Dermatological Drugs Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. Competitive Insights
    • 9.4.2.4. U.S. Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. Competitive Insights
    • 9.4.3.4. Canada Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Competitive Insights
    • 9.4.4.4. Mexico Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. Competitive Insights
    • 9.5.2.4. UK Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Competitive Insights
    • 9.5.3.4. Germany Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. Competitive Insights
    • 9.5.4.4. France Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Competitive Insights
    • 9.5.5.4. Italy Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Competitive Insights
    • 9.5.6.4. Spain Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Competitive Insights
    • 9.5.7.4. Denmark Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Competitive Insights
    • 9.5.8.4. Sweden Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Competitive Insights
    • 9.5.9.4. Norway Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Competitive Insights
    • 9.6.2.4. China Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Japan
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. Competitive Insights
    • 9.6.3.4. Japan Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. Competitive Insights
    • 9.6.4.4. India Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Competitive Insights
    • 9.6.5.4. Australia Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. Competitive Insights
    • 9.6.6.4. South Korea Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Competitive Insights
    • 9.6.7.4. Thailand Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Competitive Insights
    • 9.7.2.4. Brazil Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. Competitive Insights
    • 9.7.3.4. Argentina Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. Competitive Insights
    • 9.8.2.4. South Africa Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Competitive Insights
    • 9.8.3.4. Saudi Arabia Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. Competitive Insights
    • 9.8.4.4. UAE Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Competitive Insights
    • 9.8.5.4. Kuwait Dermatological Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. AbbVie Inc.
    • 10.5.1.1. Participant's Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Recent Developments/ Strategic Initiatives
  • 10.5.2. Pfizer Inc.
    • 10.5.2.1. Participant's Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Recent Developments/ Strategic Initiatives
  • 10.5.3. GSK plc.
    • 10.5.3.1. Participant's Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Recent Developments/ Strategic Initiatives
  • 10.5.4. Sun Pharmaceutical Industries Ltd.
    • 10.5.4.1. Participant's Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Recent Developments/ Strategic Initiatives
  • 10.5.5. GALDERMA
    • 10.5.5.1. Participant's Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Recent Developments/ Strategic Initiatives
  • 10.5.6. Amgen Inc.
    • 10.5.6.1. Participant's Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Recent Developments/ Strategic Initiatives
  • 10.5.7. Johnson & Johnson Services, Inc.
    • 10.5.7.1. Participant's Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Recent Developments/ Strategic Initiatives
  • 10.5.8. Novartis AG
    • 10.5.8.1. Participant's Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Recent Developments/ Strategic Initiatives
  • 10.5.9. Eli Lilly and Company
    • 10.5.9.1. Participant's Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Recent Developments/ Strategic Initiatives
  • 10.5.10. Almirall, S.A
    • 10.5.10.1. Participant's Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Recent Developments/ Strategic Initiatives
  • 10.5.11. Bausch Health Companies Inc.
    • 10.5.11.1. Participant's Overview
    • 10.5.11.2. Financial Performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Recent Developments/ Strategic Initiatives